Basic Information
ID DDInter667
Drug Type small molecule
Molecular Formula C22H23N3O4
Molecular Weight 393.436
CAS Number 183321-74-6
Description Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
ATC Classification L01EB02
IUPAC Name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
InChI AAKJLRGGTJKAMG-UHFFFAOYSA-N
Canonical SMILES COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Useful Links DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB PharmGKB Therapeutic Targets Database Wikipedia ChEMBL ZINC
Interactions with Erlotinib
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note